Therapeutic Protein Glycation Kinetics for Potency Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to predict and manage glycation levels and potency of therapeutic biomolecules like monoclonal antibodies, which can impact their functionality due to unpredictable glycation during production, storage, and in vivo administration, lacking a reliable framework for analysis.
Innovation Solution
A method to predict glycation percentage by determining de-glycation rates at different temperatures and pH values, using data-fitting procedures to infer glycation percentages, and maintaining glycation within a predetermined range by adjusting glucose concentrations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current analysis methods (amino acid sequence or structural motif analysis) are used to predict glycation, then the process is simple and quick, but the prediction reliability is insufficient
Solution Approach 1:
The patent changes the prediction parameters from static amino acid sequences or structural motifs to dynamic kinetic parameters (de-glycation rates) measured under controlled conditions. By determining de-glycation rates at multiple temperatures and pH values, the system creates a comprehensive kinetic profile that reliably predicts glycation behavior in vivo, resolving the contradiction between prediction reliability and method complexity.
Solution Approach 2:
The patent implements a feedback mechanism where de-glycation rate data obtained under controlled in vitro conditions is used to predict and adjust glycation expectations in vivo. This feedback loop allows the system to account for the reversible nature of glycation and provide accurate predictions about protein behavior in different physiological contexts, significantly improving prediction reliability.
2Productivity
If glycation is allowed to occur during cell culture and storage, then the biomolecule can be produced and stored, but the potency and biological activity are compromised
Solution Approach 1:
The patent applies preliminary action by measuring de-glycation rates under controlled conditions before the actual therapeutic use. This allows the system to predict future glycation states and adjust formulation or storage conditions proactively, preventing potency loss rather than reacting to it after occurrence.
Solution Approach 2:
The patent recognizes that glycation is a dynamic, reversible process rather than a static modification. By measuring de-glycation rates and using kinetic models, the system can predict how glycation levels will change over time under different conditions, allowing for dynamic adjustment of storage or formulation parameters to maintain potency.
3Measurement precision
If de-glycation rates are measured at multiple temperatures and pH values, then the prediction accuracy is improved, but the time and resources required increase
Solution Approach 1:
The patent systematically varies temperature and pH parameters to obtain comprehensive de-glycation rate data. By measuring at multiple temperatures (including physiological temperature) and multiple pH values, the system builds a robust kinetic profile that enables accurate predictions across different conditions, justifying the increased measurement time through significantly improved precision.
Solution Approach 2:
The patent creates a universal prediction framework that can apply to different biomolecules and conditions by establishing general kinetic relationships. The de-glycation rates measured under various conditions serve multiple purposes: predicting in vivo glycation, optimizing storage conditions, and adjusting formulation, thereby justifying the comprehensive measurement approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate prediction and control of glycation levels, ensuring therapeutic biomolecule potency and reducing adverse reactions such as cytokine release syndrome by formulating with specific glucose concentrations.
Implementation Method 1
determining a first set of de-glycation rates for a first temperature set over a first time duration; inferring a second set of one or more de-glycation rates for a second temperature set based on the first set of de-glycation rates
Implementation Method 2
using the second set of one or more de-glycation rate(s) to predict the glycation percentage at any temperature corresponding to the second temperature set and over a duration encompassed by a second predetermined time frame
Implementation Method 3
maintaining glycation within a predetermined range by adjusting glucose concentrations
Data Source
AI summary
Embodiments provide for methods of predicting glycation percentage of an amino acid in a therapeutic biomolecule. In one example, a method of predicting a glycation percentage of an amino acid in a biomolecule includes determining a first set of rates for a de-glycation reaction for a first set of temperatures, inferring a second set of one or more rate(s) for the de-glycation reaction for a second set of temperatures, and using the second set of one or more rate(s) to predict the glycation percentage at any temperature corresponding to the second set of temperatures and over any time duration. Also provided are methods for maintaining a glycation percentage of an amino acid within a predetermined glycation percentage range over a shelf-life of a therapeutic biomolecule, and methods for either reducing or increasing a potency of a therapeutic biomolecule in a subject at a time of administration.